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Abstract
The purpose of this study was to test the influence of 2.4 g/d fish oil n-3 polyunsaturated fatty acids (n-3 PUFA) 
over 6 wk on exercise performance, inflammation, and immune measures in 23 trained cyclists before and after a 
3-d period of intense exercise. Participants were randomized to n-3 PUFA (n = 11; 2,000 mg eicosapentaenoic 
acid [EPA], 400 mg docosahexaenoic acid [DHA]) or placebo (n = 12) groups. They ingested supplements under 
double-blind methods for 6 wk before and during a 3-d period in which they cycled for 3 hr/d at ~57% Wmax 
with 10-km time trials inserted during the final 15 min of each 3-hr bout. Blood and saliva samples were collected 
before and after the 6-wk supplementation period, immediately after the 3-hr exercise bout on the third day, 
and 14 hr postexercise and analyzed for various immune-function and inflammation parameters. Supplementation 
with n-3 PUFA resulted in a significant increase in plasma EPA and DHA but had no effect on 10-km time-trial 
performance; preexercise outcome measures; exercise-induced increases in plasma cytokines, myeloperoxidase, 
blood total leukocytes, serum C-reactive protein, and creatine kinase; or the decrease in the salivary IgA:protein 
ratio. In conclusion, 6 wk supplementation with a large daily dose of n-3 PUFAs increased plasma EPA and DHA 
but had no effect on exercise performance or in countering measures of inflammation and immunity before or 
after a 3-d period of 9 hr of heavy exertion.
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N-3 Polyunsaturated Fatty Acids Do Not
Alter Immune and Inflammation Measures 
in Endurance Athletes 
David C. Nieman, Dru A. Henson, Steven R. McAnulty, Fuxia 
Jin, and Kendra R. Maxwell1 
The purpose of this study was to test the influence of 2.4 g/d fish oil n-3 
polyunsaturated fatty acids (n-3 PUFA) over 6 wk on exercise performance, 
inflammation, and immune measures in 23 trained cyclists before and after a 3-d 
period of intense exercise. Participants were randomized to n-3 PUFA (n = 11; 
2,000 mg eicosapentaenoic acid [EPA], 400 mg docosahexaenoic acid [DHA]) or 
placebo (n = 12) groups. They ingested supplements under double-blind methods 
for 6 wk before and during a 3-d period in which they cycled for 3 hr/d at ~57% 
Wmax with 10-km time trials inserted during the final 15 min of each 3-hr bout. 
Blood and saliva samples were collected before and after the 6-wk 
supplementation period, immediately after the 3-hr exercise bout on the third day, 
and 14 hr postexercise and analyzed for various immune-function and 
inflammation parameters. Supplementation with n-3 PUFA resulted in a 
significant increase in plasma EPA and DHA but had no effect on 10-km time-
trial performance; preexercise outcome measures; exercise-induced increases in 
plasma cytokines, myeloperoxidase, blood total leukocytes, serum C-reactive 
protein, and creatine kinase; or the decrease in the salivary IgA:protein ratio. In 
conclusion, 6 wk supplementation with a large daily dose of n-3 PUFAs increased 
plasma EPA and DHA but had no effect on exercise performance or in countering 
measures of inflammation and immunity before or after a 3-d period of 9 hr of 
heavy exertion. 
Keywords: cytokines, leukocytes, salivary IgA, myeloperoxidase 
Transient inflammation and immune dysfunction are part of the normal human 
response to prolonged and intense exercise and are characterized in part by 
production of inflammatory cytokines, acute-phase proteins, and oxidative stress 
from reactive oxygen species, as well as alterations in both innate and adaptive 
immunity (Nieman, 2007; Nieman et al., 2007; Toft et al., 2000). 
At sufficiently high intakes, long-chain n-3 polyunsaturated fatty acids (n-3 
PUFAs), as found in oily fish and fish oils, decrease the production of inflammatory 
1The authors are with the Dept. of Health, Leisure, and Exercise Science, Appalachian State University, 
Boone, NC 28608. 
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eicosanoids, cytokines, and reactive oxygen species and have immunomodulatory 
effects (Calder, 2008; Fritsche, 2006; Richard, Kefi, Barbe, Bausero, & Visioli, 
2008). As reviewed by Calder (2006a, 2006b, 2007, 2008), long-chain n-3 PUFAs 
act both directly (e.g., by replacing arachidonic acid as an eicosanoid substrate and 
inhibiting arachidonic acid metabolism) and indirectly (e.g., by altering the 
expression of inflammatory genes through effects on transcription-factor activation). 
Epidemiological studies suggest an inverse relationship between C-reactive protein 
and a diet rich in marine products (Niu et al., 2006). Experimental studies indicate 
that n-3 PUFAs exert anti-inflammatory effects in part by decreasing cytokine 
release from a variety of cells and limiting leukocyte chemotaxis and the expression 
of adhesion molecules (Calder, 2008; De Caterina, Liao, & Libby, 2000). The 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) membrane 
composition of immune cells can be altered by long-term ingestion of n-3 PUFAs, 
thereby influencing phagocytosis, T-cell signaling, and antigen presentation 
capabilities (Calder, 2007). 
Thus, n-3 PUFAs exert anti-inflammatory and immunomodulatory effects and 
may act as nutritional countermeasures to exercise-induced inflammation and 
immune dysfunction for athletes. Simopoulos (2007) has reasoned that most athletes 
need 1–2 g marine n-3 PUFAs per day to counter excessive oxygen-radical 
formation, inflammation, and trauma from high-intensity exercise and the high n-6 
PUFA levels of the Western diet. Few human studies, however, have been conducted 
to assess the anti-inflammatory and immunomodulatory influence of n-3 PUFAs in 
an exercise context, and results are mixed. An early study suggested that 3 weeks 
supplementation with 1.75 g EPA and 1.05 g DHA per day lowered plasma levels of 
acute-phase proteins before exercise and altered their pattern of change after exercise 
(Ernst, Saradeth, & Achhammer, 1991). Other studies showed an enhancement in T-
cell function and a decrease in production of tumor-necrosis factor alpha with 6 
weeks of 1.8 g/day n-3 PUFA supplementation by elite swimmers (Andrade, 
Ribeiro, Bozza, Costa Rosa, & do Carmo, 2007) and an improvement in postexercise 
lung function and a decrease in sputum cytokine concentrations with 3 weeks 
ingestion of 5.2 g/day n-3 PUFAs by asthmatic patients with a history of exercise-
induced bronchoconstriction (Mickleborough, Lindley, Ionescu, & Fly, 2006; 
Mickleborough, Murray, Ionescu, & Lindley, 2003). In contrast, Toft et al. (2000) 
showed that 6 weeks supplementation with 3.6 g n-3 PUFA (53% EPA, 31% DHA) 
did not counter increases in tumor-necrosis factor alpha, IL-6, or blood neutrophil 
counts during the 3 hr after a marathon competition. 
Limited data suggest that n-3 PUFA supplementation may improve exercise 
performance by increasing stroke volume and cardiac output, decreasing systemic 
vascular resistance, and improving parasympathetic–sympathetic balance (Ninio, 
Hill, Howe, Buckley, & Saint, 2008; Walser & Stebbins, 2008). One study reported 
a trend for improvement in exercise time to fatigue (after a 75-min exercise preload) 
after 4 g/day n-3 PUFA supplementation for 1 month (Huffman, Altena, 
Mawhinney, & Thomas, 2004), whereas 2.64 g/day n-3 PUFA intake by soccer 
athletes for 10 weeks had no effect on maximal aerobic and anaerobic power or 
running performance (Raastad, Høstmark, & Strømme, 1997). 
Using a randomized, double blinded, placebo-controlled research design, we 
tested the influence of 2.4 g/day n-3 PUFA over 6 weeks on exercise performance, 
inflammation, and immune measures in 23 trained cyclists before and after a 3-day 
period of intense exercise. This research design allowed us to measure the chronic 
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effect of n-3 PUFA supplementation on inflammation and immune function after an 
overnight fast in cyclists during normal training and as a countermeasure to acute 
exercise-induced changes in these parameters. 
Methods 
Participants 
Twenty-three trained cyclists were recruited and tested as experimental participants 
through local and college cycling clubs. Written informed consent was obtained 
from each participant, and the experimental procedures were approved by the 
institutional review board of Appalachian State University. 
Research Design 
Within 1 week before the start of supplementation, participants reported to the 
university’s human performance laboratory for orientation and measurement of 
cardiorespiratory fitness. VO2max was determined using a graded maximal protocol 
(25-W increase every 2 min, starting at 150 W) with the participants using their own 
bicycles on CompuTrainer Pro Model 8001 trainers (RacerMate, Seattle, WA). 
Oxygen uptake and ventilation were measured using the MedGraphics CPX 
metabolic system (MedGraphics Corp., St. Paul, MN). Heart rate was measured 
using a chest heart-rate monitor (Polar Electro Inc., Woodbury, NY). Basic 
demographic and training data were obtained through a questionnaire. Body 
composition was assessed by hydrostatic weighing using an electronic load-cell 
system (Exertech, Dresbach, MN). Estimated residual volume was measured using 
Goldman and Buskirk’s (1961) equation, and Siri’s (1961) equation. 
Participants agreed to avoid using large-dose vitamin/mineral supplements 
(above 100% of recommended dietary allowances), herbs, and medications known to 
affect immune function during the course of the study. During orientation, a dietitian 
instructed the participants to follow a diet moderate in carbohydrate (using a food 
list) the weekend before and during the 3-day intensified exercise period. We have 
shown in previous studies that participants average 55–60% of energy from 
carbohydrates using this food list and that randomized groups do not differ in total 
energy intake (Nieman et al., 2007). At 12:00–12:30 p.m. before each 3-hr cycling 
bout, participants ingested a standardized liquid meal (Boost Plus, Mead Johnson 
Nutritionals, Evansville, IN) with an energy level of 63 kJ/kg (15 kcal/kg). Boost 
Plus is a nutritionally complete, high-energy oral supplement with an energy density 
of 6.4 kJ/ml (1.52 kcal/ml) and 16% of energy as protein, 34% as fat, and 50% as 
carbohydrate. In quantities of 1,000 ml, Boost Plus exceeds daily-value 
recommendations for all major vitamins and minerals. No other food and beverage 
(other than water) was consumed from this meal until the end of the cycling bout. 
Participants ingested 0.5–1 L water per hour of cycling. 
The cyclists were randomized to n-3 PUFA or a placebo group. Under double-
blind procedures, they ingested four soft-gel capsules per day (two in the morning on 
an empty stomach at 7:00–8:00 a.m., two at 6:00–8:00 p.m. before the evening meal) 
for 6 weeks before and during a 3-day period of intensified exercise. The soft-gel 
capsules were prepared by Cooper Concepts (The Cooper Aerobics Center, Dallas, 
TX). The n-3 PUFA capsules contained a high-potency fish-oil concentrate from 
anchovy and sardines, with soybean oil, natural flavors, tocopherols, canola oil, and 
citric acid, and provided 2,000 mg EPA and 400 mg DHA (in four soft gels). The 
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placebo capsules were identical in appearance and contained the same ingredients 
but without the fish-oil concentrate. 
Before and after 6 weeks of supplementation, participants provided blood and 
saliva samples at 8:00 a.m. after an overnight fast, having avoided exercise training 
for at least 12 hr and before having ingested the morning dose of supplements. They 
then came to the laboratory for three consecutive days and cycled from 3:00 to 6:00 
p.m. at ~57% Wmax. During the test sessions, experimental participants cycled using
their own bicycles on CompuTrainer Pro Model 8001 trainers with the exercise load
set at ~57% Wmax, as in a previous study conducted in our laboratory (Nieman et al.,
2007). Metabolic measurements were made every 30 min of cycling using the
MedGraphics CPX metabolic system to verify workload. Time trials over a 10-km
distance were inserted at the end of each cycling bout (thus three total), with
distances and workload monitored using CompuTrainer MultiRider software
(version 3.0, RacerMate, Seattle, WA). Blood and saliva samples were obtained
immediately after completion of the third 3-hr exercise bout (6:00 p.m.) and then
again 14 hr later (8:00 a.m., overnight fasted, and having avoided supplements since
6:00–8:00 p.m. the previous day).
Blood Samples, C-Reactive Protein, Creatine Kinase 
Blood samples were drawn from an antecubital vein with participants in a seated 
position. Routine complete blood counts were performed by our clinical hematology 
laboratory using a Coulter STKS instrument (Coulter Electronics, Hialeah, FL), and 
the samples provided hemoglobin and hematocrit for determination of plasma 
volume change using the method of Dill and Costill (1974). Other blood samples 
were centrifuged in sodium heparin or EDTA tubes, and plasma was aliquotted and 
then stored at –80 °C before plasma cytokine analysis. Serum C-reactive protein and 
creatine kinase were measured in a clinical laboratory using an LX-20 clinical 
analyzer (Beckman, Brea, CA). 
Plasma EPA and DHA 
After addition of 500 µg butylated hydroxytoluene and 20 µg of heptadecanoic acid 
methyl ester (NU-Chek Prep, Inc., Elysian, MN) internal standards to 100 µL 
thawed plasma, lipids were extracted and methyl esters were formed after the 
mixture was added to 2 ml of methanolic 5% HCl and incubated at 80 °C for 2 hr in 
an OLS200 Shaking Waterbath (Grant Instruments Ltd., Shepreth, Cambridgeshire, 
England; Takemoto et al., 2003). The samples were cooled to room temperature on 
completion of the incubation, and the methyl esters were extracted twice with 2 ml 
of n-hexane. The top layer of the supernatant was combined and dried with N-
EVAP116 nitrogen evaporator (Organomation Associates, Inc., Berline, MA). The 
dried extract was then reconstituted in 200 µl of n-hexane supplemented with 0.05% 
butylated hydroxytoluene, of which 1 µl was injected into an HP 6890N gas 
chromatograph (Agilent Technologies, Palo Alto, CA) equipped with a 5975B Inert 
XL MSD mass spectrometer detector. A DB-WAX GC column (30 m × 320 µm × 
0.25 µm) from J&W Scientific (Agilent Technologies) was used to separate the 
methyl esters of the extracted fatty acids. Fatty-acid concentrations were calculated 
in relation to the heptadecanoic acid methyl ester internal standard peak. The 
concentration of each phospholipid fatty acid was expressed as a concentration 
(µg/ml plasma). 
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Plasma Cytokine and Myeloperoxidase Measurements 
Enzyme-linked immunosorbent assays were used, in accordance with the 
manufacturer protocol, to measure total plasma concentrations of IL-1 receptor 
antagonist (IL-1RA), interleukin-6 (IL-6 and IL-6 high sensitivity), interleukin-8 
(IL-8), and myeloperoxidase (R&D Systems, Minneapolis, MN). All samples and 
provided standards were analyzed in duplicate. High-sensitivity kits were used to 
analyze preexercise and recovery IL-6. The minimum detectable concentrations of 
IL-1ra, IL-6, IL-6 (high sensitivity), IL-8, and myeloperoxidase were <2.2pg/ml, 
<0.7 pg/ml, <0.039 pg/ml, <3.5 pg/ml, and 0.100 ng/ml, respectively. Preexercise 
and postexercise samples were analyzed on the same assay plate to decrease interkit 
assay variability. Data were analyzed with SOFTmax software (Molecular Devices, 
Sunnyvale, CA). 
Saliva was collected and stored, and volume and total protein were measured 
as previously described (Nieman et al., 2007). Salivary IgA concentrations were 
measured using a quantitative indirect competitive immunoassay provided by 
Salimetrics, LLC (State College, PA). All samples and standards were analyzed in 
duplicate. The minimum detectable concentration for the assay was <2.5 µg/ml. The 
data are expressed as concentration of sIgA relative to total protein concentration 
(µg/mg). 
Statistical Analysis 
Data are expressed as M ± SE. Data in Table 1[ID]TBL1[/ID] were compared 
between groups using Student’s t tests. All other data (Tables 2[ID]TBL2[/ID] and 
3[ID]TBL3[/ID], Figures 1[ID]FIG1[/ID] and 2[ID]FIG2[/ID]) were analyzed using 
a 2 (groups) × 4 (time points) repeated-measures ANOVA. When Box’s M 
suggested that the assumptions necessary for the univariate approach were not 
tenable, the multivariate approach to repeated-measures ANOVA was used (Pillai’s 
trace). When interaction effects were below or equal to a p value of .05, change data 
were calculated (presupplementation to one of the three other time points) and 
compared between groups using Student’s t tests, with significance set at p ≤ .05. 
This data analysis allowed group comparisons for three different effects: 6 weeks 
chronic supplementation (pre- and postsupplementation, 8:00 a.m., overnight fasted), 
acute postexercise changes, and 14 hr postexercise recovery. 
Results 
Participant characteristics and performance data for the 23 cyclists randomized to 
placebo (n = 10 men, 2 women) and n-3 PUFA (n = 9 men, 2 women) and 
completing all phases of the study are summarized in Table 1. Outcome data for 
male and female cyclists did not differ significantly and are presented together for 
each group. During the 3-hr cycling bouts, temperature averaged 22.4 ± 0.06 °C, and 
relative humidity, 35.8% ± 1.6%. 
No significant differences were found between groups for age, body 
composition, or maximal performance measures (Table 1). Participants (all 
combined) had averaged 211 ± 37.0 km/week of cycling during the previous year 
and performed 0.96 ± 0.05 hr training per day during the 6-week supplementation 
period. Thus, the 3-day intensified exercise period (9 hr exercise) represented a 2.1-
fold increase in training duration per bout at this time of the year (late winter) and a 
substantial increase overall in exercise workload and intensity. Participants in all 
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groups were able to maintain a mean power output of 56.8% ± 0.2% Wmax at an 
oxygen consumption of ~65% VO2max during the exercise bouts (Table 1). Mean 10-
km time-trial duration (average of three trials conducted during the last portion of 
each 3-hr bout) did not differ between groups (Table 1). Plasma volume change did 
not differ between groups postexercise on the third day and averaged less than 2% 
because of ingestion of 0.5–1.0 L water per hour of exercise (data not shown). 
After 6 weeks of ingesting n-3 PUFA supplements at 7:00–8:00 a.m. and 6:00–
8:00 p.m. each day, participants had overnight-fasted plasma EPA and DHA levels 
were 311% and 40%, respectively, above placebo levels, which remained 
significantly elevated immediately and 14 hr postexercise (Figures 1 and 2). Tables 2 
and 3 show that the pattern of change over time for total blood leukocytes, serum C-
reactive protein, serum creatine kinase, the ratio of salivary IgA to protein (sIgA:P), 
plasma myeloperoxidase, plasma IL-1ra, IL-6, and IL-8 did not differ significantly 
between n-3 PUFA and placebo groups. Significant exercise-induced changes (all 
participants combined) were measured for total blood leukocytes (81%), C-reactive 
protein (115%), creatine kinase (52%), sIgA:P (–39%), myeloperoxidase (72%), IL-
8 (50%), IL-6 (664%), and IL-1ra (101%). 
Discussion 
Despite 6 weeks ingestion of 2.4 g/day marine n-3 PUFA supplements by trained 
cyclists and a significant increase in their plasma EPA and DHA, no group 
differences in inflammation or immune outcomes relative to placebo were measured 
before or after a 3-day period of intensified exercise. In addition, n-3 PUFA 
supplementation had no effect on 10-km time-trial performance. 
Most of the outcome measures included in this study increased after the third 
day of exercise, reflecting the acute but normal inflammatory response of prolonged 
and intensive exertion. Despite the well-established anti-inflammatory effects of n-3 
PUFAs (Calder 2006b, 2008) and the promotion of EPA and DHA supplements for 
endurance athletes as anti-inflammatory countermeasures to intensive exercise 
(Simopoulos, 2007), the trained cyclists in this study experienced no measurable 
anti-inflammatory effects from n-3 PUFA relative to placebo. These findings are in 
agreement with those of Toft et al. (2000), who showed no effects of 6 weeks 
supplementation with 3.6 g n-3 PUFA (53% EPA and 31% DHA) on muscle 
damage, race performance, blood neutrophil counts, or plasma cytokine levels in 10 
runners competing in the Copenhagen Marathon, compared with 10 marathoners not 
using n-3 PUFA supplements. In that study, EPA increased and arachidonic acid 
decreased in blood mononuclear cells, and the authors reasoned that the 6-week 
dosing regimen was not only adequate but that larger doses for a longer time period 
would be unlikely to have any effects on exercise-induced cytokine production. 
Although Toft et al.’s study did not include a placebo control, use double-blinded 
methods, or include a presupplementation blood measure, our results using a 
stronger research design extend and confirm this conclusion. 
Other exercise-related n-3 PUFA-supplementation studies are difficult to apply 
to our research design and do not provide strong evidence of anti-inflammatory 
effects in trained participants (Andrade et al., 2007; Ernst et al., 1991). Large-dose n-
3 PUFA supplementation for 3 weeks appears to be effective in reducing 
inflammation and exercise-induced bronchospasm symptoms in asthmatic patients 
(Mickleborough et al., 2006). These findings are in concert with the growing 
realization that EPA and DHA supplementation is more likely to exert anti-
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inflammatory and immunomodulatory effects in diseased patients or in those at high 
risk for disease than in healthy individuals(Kew et al., 2003; Kew et al., 2004; Sijben 
& Calder, 2007; Yusof, Miles, & Calder, 2008). Although unstudied, untrained 
participants may experience greater anti-inflammatory effects from n-3 PUFA 
supplementation after exercise than trained participants who have developed 
endogenous anti-inflammatory defenses (Flynn & McFarlin, 2006). 
The proposed improvement in exercise performance with n-3 PUFA 
supplementation was not supported in our study. Walser and Stebbins (2008) 
reported increased stroke volume, cardiac output, and oxygen delivery and decreased 
systemic vascular resistance in untrained participants performing 20 min of cycle-
ergometer exercise after 6 weeks of 5 g/day EPA and DHA supplementation. Ninio 
et al. (2008) demonstrated that 12 weeks supplementation with 1.92 g/day EPA and 
DHA reduced resting and submaximal-exercise heart rates and increased 
parasympathetic activity in sedentary, overweight adults. Evidence showing that 
these results extend to improved endurance performance in aerobically trained 
participants, however, is lacking (Huffman et al., 2004; Raastad et al., 1997; Toft et 
al., 2000). For example, 2.64 g/day EPA and DHA supplementation over 10 weeks 
by male soccer athletes did not improve maximal aerobic power, anaerobic power, 
and running performance relative to a placebo group despite increases in plasma 
EPA and DHA of 175% and 40%, respectively (Raastad et al.). 
In conclusion, 2.4 g/day EPA and DHA supplementation for 6 weeks by 
trained cyclists did not improve 10-km time-trial performance or alter measures of 
inflammation and immunity before and after 3 days of prolonged and intensive 
exercise when compared with placebo. These results do not support the 
recommendation by Simopoulos (2007) that most endurance athletes ingest 1–2 
g/day EPA and DHA to counter the trauma and inflammation induced by high-
intensity exercise. 
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Figure 1 — Plasma eicosapentaenoic acid (EPA) before and after 6 weeks 
supplementation, immediately postexercise after 3 days cycling (3 hr/day), and 14 hr 
postexercise. PUFA = polyunsaturated fatty acids. Group × Time interaction p < .001. *p 
< .05, change from presupplementation relative to placebo. 
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Figure 2 — Plasma docosahexaenoic acid (DHA) before and after 6 weeks 
supplementation and immediately and 14 hr postexercise. PUFA = polyunsaturated fatty 
acids. Group × Time interaction p = .009. *p < .05, change from presupplementation 
relative to placebo. 
 
 
 
Table 1 Participant Characteristics and Performance Measures, 
M ± SE 
Variable Placebo (n = 12) n-3 PUFA (n = 11) p 
Baseline measures    
 age (years) 26.9 ± 2.8 24.1 ± 2.4 .460 
 body mass (kg) 67.4 ± 3.8 68.9 ± 3.0 .761 
 VO2peak (ml ∙ kg
−1 ∙ min−1) 58.8 ± 3.1 62.9 ± 3.8 .408 
 powermax (W) 251 ± 18.5 284 ± 13.9 .172 
 HRmax (beats/min) 185 ± 2.8 188 ± 3.0 .362 
 body composition (% fat) 16.4 ± 2.7 13.7 ± 1.8 .431 
Performance measures    
 mean power (W) 143 ± 10.3 162 ± 8.1 .164 
 power (%Wmax) 56.8 ± 0.2 56.8 ± 0.2 .822 
 mean HR (beats/min) 144 ± 3.4 141 ± 2.2 .322 
 HR (%HRmax) 78.2 ± 1.1 74.8 ± 1.4 .069 
 mean VO2 (ml/min) 2,589 ± 180 2,725 ± 170 .590 
 VO2 (%VO2max) 66.3 ± 3.0 64.2 ± 3.2 .642 
 10-km time trials (min) 13.7 ± 2.2 12.7 ± 0.3 .171 
Note. PUFA = polyunsaturated fatty acids; VO2 = volume of oxygen consumption; HR = heart rate. 
Performance measures represent the mean of 3 exercise sessions. 
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Table 2 Plasma Measures Before and After 6 Weeks 
Supplementation and Immediately and 14 hr Postexercise 
Variable Presuppl Postsuppl Postexerc 
14 hr 
postexerc p 
Blood leukocytes 
(109/L) 
    
.331 
 placebo 5.83 ± 0.28 5.85 ± 0.33 9.94 ± 0.70 6.23 ± 0.41  
 n-3 PUFA 6.24 ± 0.24 5.90 ± 0.23 11.24 ± 1.13 5.97 ± 0.19  
C-reactive protein 
(mg/L) 
    
.758 
 placebo 2.09 ± 0.74 1.44 ± 0.49 3.86 ± 0.91 3.20 ± 0.77  
 n-3 PUFA 2.10 ± 0.42 2.11 ± 0.66 3.78 ± 0.94 3.51 ± 0.90  
Creatine kinase (ukat/L)     .196 
 placebo 143 ± 38.8 141 ± 19.7 248 ± 79.6 177 ± 40.2  
 n-3 PUFA 230 ± 60.9 224 ± 51.8 207 ± 30.5 149 ± 21.5  
Salivary IgA:protein 
(µg/mg) 
    
.436 
 placebo 80.8 ± 17.7 83.6 ± 18.2 34.7 ± 6.0 116.9 ± 12.0  
 n-3 PUFA 56.8 ± 8.3 56.9 ± 11.0 36.7 ± 7.8 87.7 ± 13.0  
Myeloperoxidase 
(ng/ml) 
    
.631 
 placebo 109 ± 11.8 103 ± 10.2 156 ± 16.8 78.7 ± 5.9  
 n-3 PUFA 121 ± 16.8 96.0 ± 10.7 174 ± 32.2 111 ± 19.0  
Note. PUFA = polyunsaturated fatty acids. p represents Group (2) × Time (4) interaction. 
Significant time effects were shown for all variables listed (p < .025[AUQ1]). 
Table 3 Plasma Cytokine Levels Before and After 6 Weeks 
Supplementation and Immediately and 14 hr Postexercise 
Variable Presuppl Postsuppl Postexerc 14 hr postexerc p 
IL-1ra (pg/ml)     .710 
 placebo 275 ± 30.4 225 ± 22.8 467 ± 118 232 ± 22.5  
 n-3 PUFA 259 ± 32.2 235 ± 28.6 538 ± 166 298 ± 56.9  
IL-6 (pg/ml)     .699 
 placebo 1.07 ± 0.11 1.14 ± 0.19 9.13 ± 1.38 1.36 ± 0.24  
 n-3 PUFA 1.09 ± 0.21 1.19 ± 0.26 7.01 ± 1.65 1.44 ± 0.28  
IL-8 (pg/ml)     .742 
 placebo 19.1 ± 4.0 18.0 ± 3.8 23.5 ± 4.2 19.1 ± 4.2  
 n-3 PUFA 19.9 ± 3.1 20.5 ± 3.2 22.6 ± 3.9 19.3 ± 2.9  
Note. p value represents Group (2) × Time (4) interaction. Significant time effects were shown for 
all variables listed (p < .05). 
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